All Articles
The first oncology biosimilar was approved in the United States in 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, the University of Texas at Austin. Read More ›
Over the past several years, physician office–based infusion services have been migrating to the hospital outpatient setting. The 2 main reasons for this shift can be seen as (1) financial pressures that have made the private practice model increasingly difficult to sustain, and (2) hospitals generally enjoy better payment terms than private practices, and therefore generate higher margins, particularly for hospitals with access to the 340B drug pricing program. Read More ›